High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector.

Retroviral vector-mediated HSC gene therapy has been used to treat individuals with a number of life-threatening diseases. However, some patients with SCID-X1 developed retroviral vector-mediated leukemia after treatment. The selective growth advantage of gene-modified cells in patients with SCID-X1 suggests that the transgene may have played a role in leukemogenesis. Here we report that 2 of 2 dogs and 1 of 2 macaques developed myeloid leukemia approximately 2 years after being transplanted with cells that overexpressed homeobox B4 (HOXB4) and cells transduced with a control gammaretroviral vector that did not express HOXB4. The leukemic cells had dysregulated expression of oncogenes, a block in myeloid differentiation, and overexpression of HOXB4. HOXB4 knockdown restored differentiation in leukemic cells, suggesting involvement of HOXB4. In contrast, leukemia did not arise from the cells carrying the control gammaretroviral vector. In addition, leukemia did not arise in 5 animals with high-level marking and polyclonal long-term repopulation following transplantation with cells transduced with an identical gammaretrovirus vector backbone expressing methylguanine methyltransferase. These findings, combined with the absence of leukemia in many other large animals transplanted with cells transduced with gammaretroviral vectors expressing genes other than HOXB4, show that HOXB4 overexpression poses a significant risk of leukemogenesis. Our data thus suggest the continued need for caution in genetic manipulation of repopulating cells, particularly when the transgene might impart an intrinsic growth advantage.

[1]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[2]  R. Humphries,et al.  Effects of HOXB4 Overexpression on Ex Vivo Expansion and Immortalization of Hematopoietic Cells from Different Species , 2007, Stem cells.

[3]  Christine Kinnon,et al.  Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.

[4]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[5]  Daniel G. Miller,et al.  Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  C. Baum.  Insertional mutagenesis in gene therapy and stem cell biology , 2007, Current opinion in hematology.

[7]  A. Fischer,et al.  Gene therapy for severe combined immunodeficiency: are we there yet? , 2007, The Journal of clinical investigation.

[8]  Daniel G. Miller,et al.  Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. , 2007, Human gene therapy.

[9]  C. Shaw,et al.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. , 2007, Blood.

[10]  D. Hilton,et al.  The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways , 2007, Current opinion in hematology.

[11]  Lawrence D True,et al.  Human cancers express a mutator phenotype , 2006, Proceedings of the National Academy of Sciences.

[12]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[13]  Aaron Bensimon,et al.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.

[14]  Kathryn L. Parsley,et al.  Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  T. Lu,et al.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[17]  C. von Kalle,et al.  Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. , 2006, Blood.

[18]  B. Storer,et al.  Competing Interests: The authors , 2004 .

[19]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[20]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[21]  C. von Kalle,et al.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.

[22]  R. Humphries,et al.  Hox Genes: From Leukemia to Hematopoietic Stem Cell Expansion , 2005, Annals of the New York Academy of Sciences.

[23]  B. Fehse,et al.  Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.

[24]  T. Neff,et al.  Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. , 2005, Blood.

[25]  S. Carotta,et al.  HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Humphries,et al.  Differential and Common Leukemogenic Potentials of Multiple NUP98-Hox Fusion Proteins Alone or with Meis1 , 2004, Molecular and Cellular Biology.

[27]  C. von Kalle,et al.  Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  N. Copeland,et al.  Gene Therapy Insertional Mutagenesis Insights , 2004, Science.

[29]  David A. Williams,et al.  Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. , 2003, The Journal of clinical investigation.

[30]  J. Krosl,et al.  In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein , 2003, Nature Medicine.

[31]  Takuro Nakamura,et al.  A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. , 2003, Blood.

[32]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[33]  A. Rimek,et al.  High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. , 2003, Blood.

[34]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[35]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[36]  G. Sauvageau,et al.  HOXB4-Induced Expansion of Adult Hematopoietic Stem Cells Ex Vivo , 2002, Cell.

[37]  G. Sauvageau,et al.  HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. , 2001, Experimental hematology.

[38]  C. Buske,et al.  Homeobox genes in leukemogenesis. , 2000, International journal of hematology.

[39]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[40]  B. Sorrentino,et al.  Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. , 1998, Blood.

[41]  U. Thorsteinsdóttir,et al.  Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. , 1995, Genes & development.

[42]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.